在这三种主流理论中，HSCs 的缺乏或衰老被认为是导致造血功能障碍的主

Among these three mainstream theories, the lack or aging of HSCs is considered to be the main cause of hematopoietic dysfunction. It is of great practical significance to find a candidate drug that can effectively promote the proliferation of HSCs and enhance the activity of bone marrow hematopoietic function. solved problem. Although G-CSF, EPO, PLT or direct blood transfusion are the first choices for clinical treatment of myelosuppression, these methods are relatively expensive, do not have long-lasting effects, and require repeated administration [80, 81], and their side effects are also unacceptable for most patients.

In these three mainstream theories, the lack or aging of HSCs is considered to be the main cause of hematopoietic dysfunction. Looking for a candidate drug that can effectively promote the proliferation of HSCs and enhance the activity of bone marrow hematopoietic function has important practical significance, and it is also an urgent problem to be solved. Although G-CSF, EPO, PLT or direct blood transfusion are the first choice for clinical treatment of bone marrow suppression, these methods are relatively expensive, the effect is not lasting, and need to be applied repeatedly [80, 81], and the side effects they bring are unbearable for most patients.

Among these three mainstream theories, the lack or aging of HSCs is considered as the main cause of hematopoietic dysfunction. It is of great practical significance and urgent problem to find a candidate drug that can effectively promote the proliferation of HSCs and enhance the hematopoietic activity of bone marrow. Although G-CSF, EPO, PLT or direct blood transfusion are the first choice for clinical treatment of myelosuppression, these methods are relatively expensive, do not last long, need repeated administration [80, 81], and the side effects they bring are unbearable for most patients.